Convergence Investment Partners’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $211K | Sell |
420
-64
| -13% | -$30.7K | 0.02% | 236 |
|
|
2026
Q1 | $238K | Sell |
484
-26
| -5% | -$14.1K | 0.04% | 226 |
|
|
2025
Q4 | $296K | Buy |
510
+41
| +9% | +$23.2K | 0.06% | 222 |
|
|
2025
Q3 | $228K | Buy |
+469
| New | +$218K | 0.05% | 242 |
|
|
2025
Q2 | – | Sell |
-508
| Closed | -$253K | – | 285 |
|
|
2025
Q1 | $253K | Sell |
508
-136
| -21% | -$73.7K | 0.07% | 223 |
|
|
2024
Q4 | $335K | Buy |
644
+12
| +2% | +$6.6K | 0.07% | 205 |
|
|
2024
Q3 | $391K | Sell |
632
-25
| -4% | -$14.8K | 0.11% | 189 |
|
|
2024
Q2 | $364K | Sell |
657
-13
| -2% | -$7.45K | 0.11% | 197 |
|
|
2024
Q1 | $390K | Sell |
670
-1
| -0.1% | -$561 | 0.15% | 163 |
|
|
2023
Q4 | $356K | Sell |
671
-13
| -2% | -$6.29K | 0.19% | 117 |
|
|
2023
Q3 | $346K | Buy |
684
+2
| +0.3% | +$1.07K | 0.2% | 107 |
|
|
2023
Q2 | $356K | Sell |
682
-22
| -3% | -$11.9K | 0.2% | 108 |
|
|
2023
Q1 | $406K | Buy |
704
+6
| +0.9% | +$3.38K | 0.24% | 101 |
|
|
2022
Q4 | $385K | Sell |
698
-22
| -3% | -$11.7K | 0.23% | 105 |
|
|
2022
Q3 | $365K | Sell |
720
-26
| -3% | -$14.6K | 0.24% | 102 |
|
|
2022
Q2 | $405K | Sell |
746
-14
| -2% | -$7.71K | 0.25% | 100 |
|
|
2022
Q1 | $449K | Sell |
760
-8
| -1% | -$4.6K | 0.23% | 107 |
|
|
2021
Q4 | $513K | Sell |
768
-37
| -5% | -$23.1K | 0.26% | 96 |
|
|
2021
Q3 | $460K | Buy |
805
+21
| +3% | +$11.5K | 0.25% | 99 |
|
|
2021
Q2 | $396K | Sell |
784
-532
| -40% | -$251K | 0.17% | 131 |
|
|
2021
Q1 | $601K | Buy |
1,316
+472
| +56% | +$225K | 0.27% | 93 |
|
|
2020
Q4 | $393K | Buy |
844
+19
| +2% | +$8.91K | 0.2% | 113 |
|
|
2020
Q3 | $364K | Sell |
825
-90
| -10% | -$37.2K | 0.13% | 201 |
|
|
2020
Q2 | $332K | Buy |
915
+39
| +4% | +$13.1K | 0.11% | 191 |
|
|
2020
Q1 | $248K | Sell |
876
-4,435
| -84% | -$1.4M | 0.11% | 196 |
|
|
2019
Q4 | $1.73M | Buy |
5,311
+1,246
| +31% | +$378K | 0.49% | 63 |
|
|
2019
Q3 | $1.18M | Sell |
4,065
-2,670
| -40% | -$765K | 0.33% | 107 |
|
|
2019
Q2 | $1.98M | Buy |
6,735
+5,820
| +636% | +$1.6M | 0.48% | 70 |
|
|
2019
Q1 | $251K | Buy |
915
+7
| +0.8% | +$1.74K | 0.05% | 245 |
|
|
2018
Q4 | $203K | Buy |
+908
| New | +$213K | 0.05% | 293 |
|
|
2018
Q2 | – | Sell |
-747
| Closed | -$154K | – | 852 |
|
|
2018
Q1 | $154K | Buy |
+747
| New | +$157K | 0.02% | 306 |
|
Other funds holding TMO
Convergence Investment Partners's TMO Position: Q2 2026 in Review
Convergence Investment Partners reduced its Thermo Fisher Scientific (TMO) stake by 13% in Q2 2026, selling an estimated $30.7K and leaving 420 shares worth $211K. The position accounts for 0.02% of the portfolio, ranked #236.
Convergence Investment Partners first reported a position in TMO in Q1 2018 and has held it in 31 quarters since. The position peaked at $1.98M in Q2 2019. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Convergence Investment Partners held 420 shares of Thermo Fisher Scientific worth $211K as of Q2 2026.
- Convergence Investment Partners sold 64 Thermo Fisher Scientific shares in Q2 2026, an estimated $30.7K.
- Thermo Fisher Scientific made up 0.02% of Convergence Investment Partners's portfolio in Q2 2026, its #236 holding.
- Convergence Investment Partners first reported a position in Thermo Fisher Scientific in Q1 2018 and has held it in 31 quarters since.
- Convergence Investment Partners's Thermo Fisher Scientific position peaked at $1.98M in Q2 2019.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.